Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOTRIN IB vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Relief of minor aches and pains due to headache, toothache, backache, menstrual cramps, muscle aches, or minor pain of arthritis,Reduction of fever
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is approximately 2 hours (range 1.8–2.5 hours) in adults. In patients with hepatic impairment or advanced age, half-life may be prolonged. The short half-life supports dosing every 6–8 hours for analgesia.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via cytochrome P450 2C9 (CYP2C9) and, to a lesser extent, CYP2C8; undergoes glucuronidation.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal excretion of conjugated metabolites (primarily glucuronide and sulfate) accounts for approximately 90% of an absorbed dose; less than 1% is excreted unchanged. Biliary/fecal elimination constitutes about 10%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 99% bound to plasma albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Apparent volume of distribution is 0.15 L/kg (range 0.10–0.20 L/kg), consistent with low tissue penetration and high plasma protein binding.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: ~80% (rapidly and completely absorbed; first-pass metabolism reduces absolute bioavailability to 80% of the dose).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 30-60 m L/min: no adjustment needed; GFR 10-29 m L/min: reduce dose by 25-50%; GFR <10 m L/min: avoid use or reduce dose by 50%.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; maximum 40 mg/kg/day or single doses not exceeding 400 mg.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at the lowest effective dose, typically 200-400 mg every 6-8 hours; maximum 1200 mg/day; monitor renal function and potential for GI bleeding.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk. Additionally, NSAIDs cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions such as Stevens-Johnson syndrome; avoid use in late pregnancy
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to ibuprofen or any component of the formulation; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; active peptic ulcer or gastrointestinal bleeding; advanced renal disease
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Concomitant intake of alcohol may increase risk of gastrointestinal bleeding. No specific food restrictions; however, taking with food may reduce GI irritation. Avoid grapefruit juice? No significant interaction known.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Increased risk of miscarriage and cardiac defects (odds ratio 1.86 for cardiovascular malformations). Second trimester: Risk of oligohydramnios and fetal renal dysfunction. Third trimester: Known risk of premature closure of ductus arteriosus, persistent pulmonary hypertension, oligohydramnios, and necrotizing enterocolitis. Use contraindicated after 30 weeks gestation.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01). Amount ingested by infant <1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for gastrointestinal effects and renal function.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Increased volume of distribution and renal clearance in pregnancy may reduce serum concentrations. However, due to fetal risks, dose adjustments are not recommended; instead, avoid use after 30 weeks and limit to lowest effective dose with shortest duration in earlier trimesters.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Motrin IB (ibuprofen) is a nonsteroidal anti-inflammatory drug (NSAID) used for mild to moderate pain, fever, and inflammation. Onset of analgesia is within 30-60 minutes. It is more effective than acetaminophen for inflammatory pain. Maximum single OTC dose is 400 mg; maximum daily OTC dose is 1200 mg. Chronic use increases risk of GI bleeding, renal impairment, and cardiovascular events. Avoid in patients with significant renal impairment (e GFR <30), active peptic ulcer disease, or prior hypersensitivity to NSAIDs. Use with caution in patients with hypertension, heart failure, or on anticoagulants. Ibuprofen may reduce the cardioprotective effect of low-dose aspirin if taken simultaneously; separate dosing by at least 2 hours.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg (6 tablets of 200 mg) in 24 hours.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Stop use and consult a doctor if pain worsens or lasts more than 10 days, or if fever lasts more than 3 days.,Do not take with other NSAIDs (e.g., naproxen, aspirin) unless directed by a healthcare provider.,Seek medical attention immediately if signs of allergic reaction (rash, hives, swelling, difficulty breathing) or stomach bleeding (black/bloody stools, vomiting blood) occur.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOTRIN IB vs ABSTRAL, answered by our medical review team.
MOTRIN IB is a NSAID Analgesic that works by Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOTRIN IB and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOTRIN IB is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOTRIN IB and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOTRIN IB is classified as Category C. First trimester: Increased risk of miscarriage and cardiac defects (odds ratio 1.86 for cardiovascular malformations). Second trimester: Risk of oligohydramnios and fetal renal dys. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.